Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.
The main aim of the present study was to compare mucoadhesion and cellular uptake efficiency of chitosan (CS) and chitosan oligosaccharide (COS) surface-modified polymer nanoparticles (NPs) for mucosal delivery of proteins. We have developed poly (D, L-lactide-co-glycolide) (PLGA) NPs, surface-modified COS-PLGA NPs and CS-PLGA NPs, by using double emulsion solvent evaporation method, for encapsulating bovine serum albumin (BSA) as a model protein. Surface modification of NPs was confirmed using physicochemical characterization methods such as particle size and zeta potential, SEM, TEM and FTIR analysis. Both surface-modified PLGA NPs displayed a slow release of protein compared to PLGA NPs. Furthermore, we have explored the mucoadhesive property of COS as a material for modifying the surface of polymeric NPs. During in vitro mucoadhesion test, positively charged COS-PLGA NPs and CS-PLGA NPs exhibited enhanced mucoadhesion, compared to negatively charged PLGA NPs. This interaction was anticipated to improve the cell interaction and uptake of NPs, which is an important requirement for mucosal delivery of proteins. All nanoformulations were found to be safe for cellular delivery when evaluated in A549 cells. Moreover, intracellular uptake behaviour of FITC-BSA loaded NPs was extensively investigated by confocal laser scanning microscopy and flow cytometry. As we hypothesized, positively charged COS-PLGA NPs and CS-PLGA NPs displayed enhanced intracellular uptake compared to negatively charged PLGA NPs. Our results demonstrated that CS- and COS-modified polymer NPs could be promising carriers for proteins, drugs and nucleic acids via nasal, oral, buccal, ocular and vaginal mucosal routes.
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, NP Marg, Matunga, Mumbai, 400019, India.|Departments of Chemical Engineering, Institute of Chemical Technology, Matunga, Mumbai, 400019, India.
Sathish
S
Dyawanapelly
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, NP Marg, Matunga, Mumbai, 400019, India.
Uday
U
Koli
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, NP Marg, Matunga, Mumbai, 400019, India.
Vimisha
V
Dharamdasani
Departments of Chemical Engineering, Institute of Chemical Technology, Matunga, Mumbai, 400019, India. rd.jain@ictmumbai.edu.in.
Ratnesh
R
Jain
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, NP Marg, Matunga, Mumbai, 400019, India. pd.jain@ictmumbai.edu.in.
Prajakta
P
Dandekar
D002470:Cell Survival / Q000187:drug effects; D048271:Chitosan / Q000737:chemistry / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000493:pharmacokinetics; D004337:Drug Carriers / Q000737:chemistry / Q000493:pharmacokinetics*; D065546:Drug Liberation; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry / Q000493:pharmacokinetics; D009092:Mucous Membrane / Q000378:metabolism*; D053758:Nanoparticles / Q000737:chemistry* / Q000378:metabolism* / Q000648:ultrastructure; D009844:Oligosaccharides / Q000737:chemistry / Q000493:pharmacokinetics*; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry / Q000493:pharmacokinetics; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011506:Proteins / Q000737:chemistry / Q000493:pharmacokinetics*; D012710:Serum Albumin, Bovine / Q000493:pharmacokinetics
D003692:Delayed-Action Preparations; D004337:Drug Carriers; D009844:Oligosaccharides; D011506:Proteins; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D012710:Serum Albumin, Bovine; D019344:Lactic Acid; D048271:Chitosan
Chitosan; Chitosan oligosaccharide; Mucosal delivery; Nanoparticle; Poly (D, L-lactide-co-glycolide); Protein